alpha-thalassemia have had FEP and serum iron and transferrin saturation levels determined. Twelve individuals with alphathalassemia and normal transferrin saturation studies had FEP below 90 ugms/100 rnl of Rbc's. Six individuals with documented iron deficiency and alpha-thalassemia had FEP greater than 130 ugms/100 rnl as did individuals with uncomplicated iron deficiency. Micromeasurement of Rbc FEP provides a rapid means of differentiating iron deficiency from thalassemia with normal transferrin saturations. However, when alphathalassemia and iron deficiency occur together, alphathalassemia cannot be proven until the iron deficiency is corrected. At birth, the newborn infant has a heterogenous population of erythrocytes; variability exists with respect to size, shape, enzymatic capacity and hemoglobin composition. Bnploying both differential staining for fetal hemoglobin and cytophotometric techniques, the erythrocytes of term infants were examined in an attempt to relate cell size to hemoglobin composition. One-hundred and twenty cells from each infant were individually sized and subjected to microdensitometry measurements. Sixty of the cells had been eluted and counter-stained for fetal hemoglobin. The staining for fetal hemoglobin did not alter the size of the cells. Analysis revealed that as the red cells increased in size the concentration of fetal hemoglobin vithin the cells decreased significantly more than did the total hemoglobin concentration. Cells with a diameter of approximately 6 p had almost exclusively fetal hemoglobin. These findings are consistent with the hypothesis that the largest, and presumably the youngest, erythrocytes are synthesizing less fetal hemoglobin at the time of birth than cells that had been produced some weeks before. The use of cytophotometry provides a technique for following cohorts of cells with varying ages and hemoglobin canposition. A simple, rapid microfluorometric method for quantitative measurement of serum albumin binding capacity for unconjugated bilirubin CUB), utilizing a fluorescent dye, Direct Yellow 7, has been developed. Sephadex G-200 column chromatographic study revealed exclusive association of serum albumin fraction with the dye. Spectrofluorometric study demonstrated enhanced fluorescence (AF) of the dye when bound to serum albumin. The addition of increasing concentrations of UB ( 5 to 70 mg%) to adult human sera resulted in a progressive inhibition of AF with complete inhibition at 55 mg%. Multiple regression analysis yielded two significantly different slopes (p<.001), first, from 0 to 27 mg% and second slope, 27 to 55 mg%. UB concentration of 27 mg% corresponded to UB: albumin molar ratio of 0.97, while 55 mg% to 1.97. Enhanced fluorescence of the dye resulted entirely from binding of the dye to two bilirubin-binding sites on albumin, since AF was completely inhibited by addition of two moles of UB per mole of albumin. Lowered pH reduced albumin binding capacity and exposure to light increased binding capacity of icteric sera. The binding capacity of purified human serum albumin was 7.120.8 AFlgm albumin (SD) (n=4), approximately one-half that of the adult human sera, 13.4t0.5 AFlgm (SD) (n=4). while human cord sera gave 9.3t1.1 AF/gm (SD) (n=41), 30% less than that of the adult sera on albumin molar basis. In 1968-1969, previously untreated patients with ALL were given high dose combination chemotherapy (POMP). This included on days 1-5, i.v., prednisolone 1000 mg/m2; methotrexate (MTX) 7.5 mg/m2; 6-mercaptopurine (6MP) 125 mg/m2; and, on day 1, vincristine 2 mg/m2. Once remission was achieved POMP was given every 2 weeks. The doses of 6-MP and MTX were increased to maximally tolerated levels in all pts. After 6 months, bischloroethylnitrosourea (BCNU) was given for 3 days at 50 mg/ m2 and pts. were randomized to receive POMP monthly for 6 months or no further therapy. Complete remission was achieved in 61/66 pts. (91%). Median remission duration for all 61 pts. was 13 months; 48 pts. completed the initial 6 months of therapy without relapse; 24 were randomized to receive further POMP therapy and 24 to no further therapy. The further therapy group had a median remission of 20 months with 7 pts. still in initial remission. The no further therapy group had a median remission of 11 months with 2 still in initial remission. These differences are significant at the p <.05 level by the generalized Wilcoxon test. A comparable group of 35 pts. had an intermediate remission duration of 17 months. These data indicate that even with intensive therapy in the first 6 months, cure of leukemia will not be possible in the majority of pts. Prolonged therapy is required for improved remission duration. was 12 years. The procedure was performed on 4 knee joints,
RED CELL SIZE

SYNOVECTOMY IN HEMOPHILIAC HEMARTHROSIS, Stella
The % of H.B. in Hb A RBC at 3 7 O~ for 3,6,12, and 24 hrs was 4 ankle joints and 7 elbow joints. There were no instances 0,0,0 and 49.5+19.1%; in Hb Z -0,5.5,63.6, and 99.2%. The%'s o f early or late hemorrhage. The hospital time averaged 11 at 416c were 0,8.6,59.4+25.6, and 100 in Hb A RBC; and 24.0, days. Re-bleeding into the joint has been absent or 74.9,100, and 100 for HF Z RBC. Hb Z in the red cells did not markedly decreased in an average 3 year period. There was decrease until 3-6 hrs after the appearance of H.B. The % of Hb some improvement in joint range o f motion in 50% o f A remained constant. Progressive precipitation of Hb in Hb Z patients and radiologic improvement was also noted. In 2 and Hb A RBC was accompanied by increased formation of methemoselected hemophi l ia patients, synovectomy may be indicated globin, a marked decrease in reduced gl utathionk and hexokinase as a hemostatic procedure. activity, and a moderate decrease in glucose-6-phosphate dehydrogenase and pyruvate kinase activities. Thermal denaturation of hemoglobin may be a cause of fever-related anemia in pts with unstable hemoglobins. Also measurement of H.B. formation in heat-treated whole blood is a sensitive and simple technique for defining Hb Z and possibly other unstable hemoglobins.
